Article

Pfizer-J&J Drop Alzheimer's Drug Studies After Failure

Pfizer (PFE)

Johnson & Johnson (JNJ)

Inc., and Elan Corp. ended most plans to develop an Alzheimer’s drug after a second trial failure, a blow to the companies’ efforts to market the first product to slow progress of the disease.

Bapineuzumab, designed to attack the brain plaques that serve as a hallmark of Alzheimer’s, failed to improve symptoms of dementia in the second of four final-stage trials of the drug, Pfizer and J&J said yesterday in statements. Elan’s American depositary receipts fell 11 percent to $10.02 at 9:44 a.m. New York time.

Read the full story: http://tinyurl.com/9lst2tr

Source: Bloomberg

Related Videos
Parth Rali, MD
Susan Perlman, MD, an expert on Friedreich's ataxia
Susan Perlman, MD, an expert on Friedreich's ataxia
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo